$100 Million

Portola Therapeutics

Follow-on Offering

Co-Manager, March 2015

Confidentially Marketed Public Offering

Portola Pharmaceuticals is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics that could significantly advance the fields of thrombosis and other hematologic conditions. The Company's first two commercialized products are Andexxa® [coagulation factor Xa (recombinant), inactivated-zhzo], marketed in Europe as Ondexxya® (andexanet alfa), and Bevyxxa® (betrixaban). The company also is advancing Cerdulatinib, a SYK/JAK inhibitor being developed for the treatment of hematologic cancers